Rapport Therapeutics, Inc. announced positive topline results from the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures.
The trial met primary long episode endpoints with high statistical significance, and RAP-219 demonstrated a 77.8% reduction in clinical seizures with some patients achieving seizure freedom for the 8-week treatment period.
The data support the advancement of RAP-219 into Phase 3 registrational trials.
Reduction in Clinical Seizures
Patients achieved a 77.8% reduction in clinical seizures with some experiencing seizure freedom during the 8-week treatment period.
Statistical Significance
The trial met primary long episode endpoints with high statistical significance, indicating the effectiveness of RAP-219.
Advancement to Phase 3
The positive results support the advancement of RAP-219 into Phase 3 registrational trials for further evaluation.
- The Phase 2a clinical trial demonstrated a significant reduction in long episodes and clinical seizures, providing promising results for patients with drug-resistant focal onset seizures.
- The success of RAP-219 in the trial marks a potential advancement in anti-seizure medications, addressing the need for novel treatment options with meaningful benefits.
- Physicians and patients may find hope in the potential of RAP-219 to offer effective treatment and possibly achieve seizure freedom in drug-resistant focal seizure patients.
The positive topline results of the Phase 2a clinical trial of RAP-219 showcase the potential of this investigational medication in treating drug-resistant focal onset seizures. With significant reductions in clinical seizures and the promise of seizure freedom, RAP-219 stands as a hopeful advancement in epilepsy treatment options.